Laboratoires Théa

#Biotech #Laboratoires Théa #Opthalmology

Biotech partnership to advance retinal drug pipeline 

Biotechnology company Iolyx Therapeutics has entered a strategic development and commercialisation agreement with ophthalmic specialty company Laboratoires Théa to advance its retinal pipeline.  Under the license and development agreement, Iolyx has granted Théa exclusive worldwide development and commercialisation rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.  … Read More

#Business & Investment #News

RNA
#Laboratoires Théa #Mergers and acquisitions #Ophthalmology #ProQR Therapeutics #RNA

Théa acquires ProQR’s RNA ophthalmic assets

ProQR Therapeutics and Laboratoires Théa have announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M… Read More

#Business & Investment #News